MGRM vs. NPCE, CVRX, LUNG, SMTI, AVR, ZYXI, NVRO, RCEL, ELMD, and PROF
Should you be buying Monogram Orthopaedics stock or one of its competitors? The main competitors of Monogram Orthopaedics include NeuroPace (NPCE), CVRx (CVRX), Pulmonx (LUNG), Sanara MedTech (SMTI), Anteris Technologies Global (AVR), Zynex (ZYXI), Nevro (NVRO), AVITA Medical (RCEL), Electromed (ELMD), and Profound Medical (PROF). These companies are all part of the "medical equipment" industry.
Monogram Orthopaedics vs.
NeuroPace (NASDAQ:NPCE) and Monogram Orthopaedics (NASDAQ:MGRM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
NeuroPace received 29 more outperform votes than Monogram Orthopaedics when rated by MarketBeat users. However, 100.00% of users gave Monogram Orthopaedics an outperform vote while only 60.78% of users gave NeuroPace an outperform vote.
NeuroPace currently has a consensus price target of $15.20, suggesting a potential upside of 35.23%. Monogram Orthopaedics has a consensus price target of $4.00, suggesting a potential upside of 8.99%. Given NeuroPace's higher probable upside, research analysts plainly believe NeuroPace is more favorable than Monogram Orthopaedics.
In the previous week, Monogram Orthopaedics had 20 more articles in the media than NeuroPace. MarketBeat recorded 22 mentions for Monogram Orthopaedics and 2 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.20 beat Monogram Orthopaedics' score of 0.80 indicating that NeuroPace is being referred to more favorably in the media.
Monogram Orthopaedics has a net margin of 0.00% compared to NeuroPace's net margin of -36.74%. Monogram Orthopaedics' return on equity of -130.90% beat NeuroPace's return on equity.
NeuroPace has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Comparatively, Monogram Orthopaedics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.
78.8% of NeuroPace shares are held by institutional investors. Comparatively, 0.4% of Monogram Orthopaedics shares are held by institutional investors. 22.2% of NeuroPace shares are held by insiders. Comparatively, 28.1% of Monogram Orthopaedics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Monogram Orthopaedics has lower revenue, but higher earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Monogram Orthopaedics, indicating that it is currently the more affordable of the two stocks.
Summary
Monogram Orthopaedics beats NeuroPace on 11 of the 19 factors compared between the two stocks.
Get Monogram Orthopaedics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGRM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monogram Orthopaedics Competitors List
Related Companies and Tools
This page (NASDAQ:MGRM) was last updated on 3/17/2025 by MarketBeat.com Staff
